Search Results - "Ingle, Ashish M."

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study by Mossé, Yael P, Dr, Lim, Megan S, MD, Voss, Stephan D, MD, Wilner, Keith, PhD, Ruffner, Katherine, MD, Laliberte, Julie, Rolland, Delphine, Balis, Frank M, Prof, Maris, John M, Prof, Weigel, Brenda J, MD, Ingle, Ashish M, MS, Ahern, Charlotte, PhD, Adamson, Peter C, Prof, Blaney, Susan M, Prof

“…Summary Background Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma,…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report by BENDER, Julia L. Glade, LEE, Alice, WEIGEL, Brenda J, BLANEY, Susan M, REID, Joel M, BARUCHEL, Sylvain, ROBERTS, Timothy, VOSS, Stephan D, BING WU, AHERN, Charlotte H, INGLE, Ashish M, HARRIS, Pamela

“…Pazopanib, an oral multikinase angiogenesis inhibitor, prolongs progression-free survival in adults with soft tissue sarcoma (STS). A phase I pharmacokinetic…”
Get full text

Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group by MALEMPATI, Suman, WEIGEL, Brenda, CHEN, Helen X, KRAILO, Mark D, ADAMSON, Peter C, BLANEY, Susan M, INGLE, Ashish M, AHERN, Charlotte H, CARROLL, Julie M, ROBERTS, Charles T, REID, Joel M, SCHMECHEL, Stephen, VOSS, Stephan D, CHO, Steven Y

“…A phase I/II study of cixutumumab (IMC-A12) in children with refractory solid tumors was conducted. This study was designed to assess the toxicities,…”
Get full text

Pediatric Phase I Trial and Pharmacokinetic Study of Vorinostat: A Children's Oncology Group Phase I Consortium Report by FOULADI, Maryam, PARK, Julie R, ZWIEBEL, James, BLANEY, Susan M, ADAMSON, Peter C, STEWART, Clinton F, GILBERTSON, Richard J, SCHAIQUEVICH, Paula, JUNFENG SUN, REID, Joel M, AMES, Matthew M, SPEIGHTS, Roseanne, INGLE, Ashish M

“…The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of vorinostat administered as…”
Get full text

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study by GLADE BENDER, Julia L, ADAMSON, Peter C, NELSON, Marvin D, KRAILO, Mark D, INGLE, Ashish M, BLANEY, Susan M, KANDEL, Jessica J, YAMASHIRO, Darrell J, REID, Joel M, LU XU, BARUCHEL, Sylvain, SHAKED, Yuval, KERBEL, Robert S, COONEY-QUALTER, Erin M, STEMPAK, Diana, CHEN, Helen X

“…We conducted a pediatric phase I trial of the vascular endothelial growth factor (VEGF)-neutralizing antibody bevacizumab (BV). Primary aims included…”
Get full text

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study by JAKACKI, Regina I, HAMILTON, Marta, GILBERTSON, Richard J, BLANEY, Susan M, TERSAK, Jean, KRAILO, Mark D, INGLE, Ashish M, VOSS, Stephan D, DANCEY, Janet E, ADAMSON, Peter C

“…We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with…”
Get full text

A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study by HORTON, Terzah M, PATI, Debananda, BLANEY, Susan M, PLON, Sharon E, THOMPSON, Patrick A, BOMGAARS, Lisa R, ADAMSON, Peter C, INGLE, Ashish M, WRIGHT, John, BROCKMAN, Adam H, PATON, Martin

“…Purpose: A phase 1 study to determine the maximum-tolerated dose, dose-limiting toxicity, pharmacokinetics, and biological effects of bortezomib in children…”
Get full text

A pediatric phase I trial and pharmacokinetic study of ispinesib: A Children's Oncology Group phase I consortium study by Souid, Abdul-Kader, Dubowy, Ronald L., Ingle, Ashish M., Conlan, Maureen G., Sun, Junfeng, Blaney, Susan M., Adamson, Peter C.

“…Purpose To determine the maximum‐tolerated dose, dose‐limiting toxicities, and pharmacokinetics of the kinesin spindle protein inhibitor ispinesib in pediatric…”
Get full text

A Phase I Study of 17-Allylaminogeldanamycin in Relapsed/Refractory Pediatric Patients with Solid Tumors: A Children's Oncology Group Study by WEIGEL, Brenda J, BLANEY, Susan M, GILBERTSON, Richard J, KRAILO, Mark, AMES, Matthew, ADAMSON, Peter C, REID, Joel M, SAFGREN, Stephanie L, BAGATELL, Rochelle, KERSEY, John, NEGLIA, Joseph P, IVY, S. Percy, INGLE, Ashish M, WHITESELL, Luke

“…Purpose: To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein…”
Get full text

Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report by FOULADI, Maryam, FURMAN, Wayne L, WRIGHT, John, ADAMSON, Peter C, BLANEY, Susan M, CHIN, Thomas, FREEMAN, Burgess B, DUDKIN, Lorina, STEWART, Clinton F, KRAILO, Mark D, SPEIGHTS, Roseanne, INGLE, Ashish M, HOUGHTON, Peter J

“…To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the histone deacetylase…”
Get full text

Phase I Pharmacokinetic and Pharmacodynamic Study of Temozolomide in Pediatric Patients With Refractory or Recurrent Leukemia: A Children's Oncology Group Study by HORTON, Terzah M, THOMPSON, Patrick A, BLANEY, Susan M, BERG, Stacey L, ADAMSON, Peter C, INGLE, Ashish M, DOLAN, M. Eileen, DELANEY, Shannon M, HEDGE, Madhuri, WEISS, Heidi L, WU, Meng-Fen

“…To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia. Cohorts of three…”
Get full text

A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report by WIDEMANN, Brigitte C, KIM, Aerang, BALIS, Frank M, BLANEY, Susan M, FOX, Elizabeth, BARUCHEL, Sylvain, ADAMSON, Peter C, INGLE, Ashish M, BENDER, Julia Glade, BURKE, Michael, WEIGEL, Brenda, STEMPAK, Diana

“…To determine the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of sorafenib in children with refractory…”
Get full text

Phase I Trial and Pharmacokinetic Study of Pemetrexed in Children With Refractory Solid Tumors: The Children's Oncology Group by MALEMPATI, Suman, STACY NICHOLSON, H, AMES, Matthew M, ADAMSON, Peter C, REID, Joel M, BLANEY, Susan M, INGLE, Ashish M, KRAILO, Mark, STORK, Linda C, MELEMED, Allen S, MCGOVERN, Renee, SAFGREN, Stephanie

“…We report results of a phase I trial and pharmacokinetic study of pemetrexed (LY231514) in children and adolescents with refractory solid tumors. Pemetrexed is…”
Get full text

Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: A children's oncology group study by Bagatell, Rochelle, Norris, Robin, Ingle, Ashish M., Ahern, Charlotte, Voss, Stephan, Fox, Elizabeth, Little, Anthony R., Weigel, Brenda J., Adamson, Peter C., Blaney, Susan

“…Background mTOR inhibitors have activity in pediatric tumor models. A phase I trial of the mTOR inhibitor temsirolimus (TEM) with irinotecan (IRN) and…”
Get full text

Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study by DUBOIS, Steven G, SHUSTERMAN, Suzanne, ADAMSON, Peter C, BLANEY, Susan M, INGLE, Ashish M, AHERN, Charlotte H, REID, Joel M, BING WU, BARUCHEL, Sylvain, GLADE-BENDERS, Julia, IVY, Percy, GRIER, Holcombe E

“…Sunitinib is an oral multitargeted receptor tyrosine kinase inhibitor. The purpose of this study was to determine the recommended phase 2 dose,…”
Get full text

A Phase I Trial of Imetelstat in Children with Refractory or Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Study (ADVL1112) by THOMPSON, Patrick A, DRISSI, Rachid, BLANEY, Susan M, MUSCAL, Jodi A, PANDITHARATNA, Eshini, FOULADI, Maryam, INGLE, Ashish M, AHERN, Charlotte H, REID, Joel M, TONG LIN, WEIGEL, Brenda J

“…Imetelstat is a covalently-lipidated 13-mer thiophosphoramidate oligonucleotide that acts as a potent specific inhibitor of telomerase. It binds with high…”
Get full text

Phase 1 Study of Valproic Acid in Pediatric Patients with Refractory Solid or CNS Tumors: A Children's Oncology Group Report by SU, Jack M, LI, Xiao-Nan, THOMPSON, Patrick, OU, Ching-Nan, INGLE, Ashish M, RUSSELL, Heidi, LAU, Ching C, ADAMSON, Peter C, BLANEY, Susan M

“…The primary purpose of this trial was to define and describe the toxicities of oral valproic acid (VPA) at doses required to maintain trough concentrations of…”
Get full text

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report by Angiolillo, Anne L., Yu, Alice L., Reaman, Gregory, Ingle, Ashish M., Secola, Rita, Adamson, Peter C.

“…Background Despite the increasing cure rates for children with acute lymphoblastic leukemia (ALL), patients who relapse continue to have poor prognosis. The…”
Get full text

A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: A Children's Oncology Group phase I consortium study (ADVL0916) by Muscal, Jodi A., Thompson, Patrick A., Horton, Terzah M., Ingle, Ashish M., Ahern, Charlotte H., McGovern, Renee M., Reid, Joel M., Ames, Matthew M., Espinoza-Delgado, Igor, Weigel, Brenda J., Blaney, Susan M.

“…Background A pediatric Phase I trial was performed to determine the maximum‐tolerated dose, dose‐limiting toxicities (DLTs), and pharmacokinetics (PK) of…”
Get full text

A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A children's oncology group phase 1 consortium study by Hummel, Trent R., Wagner, Lars, Ahern, Charlotte, Fouladi, Maryam, Reid, Joel M., McGovern, Renee M., Ames, Matthew M., Gilbertson, Richard J., Horton, Terzah, Ingle, Ashish M., Weigel, Brenda, Blaney, Susan M.

“…Purpose We conducted a pediatric phase I study to estimate the maximum tolerated dose (MTD), dose‐limiting toxicities (DLT), and pharmacokinetic properties of…”
Get full text